Advanced search
Publication Cover
Future Oncology Volume 18, 2022 - Issue 1
Submit an article Journal homepage
3,519
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Real-World Outcomes of Second Novel Hormonal Therapy or Radium-223 Following First Novel Hormonal Therapy for mCRPC

Oliver Sartor1 Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8777-7343View further author information
ORCID Icon,
Daniel George2 Departments of Medicine & Surgery, Duke Cancer Institute, Duke University, Durham, NC, USAORCID Iconhttps://orcid.org/0000-0002-0836-8542View further author information
ORCID Icon,
Bertrand Tombal3 Division of Urology, IREC, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, BelgiumORCID Iconhttps://orcid.org/0000-0002-0093-8408View further author information
ORCID Icon,
Neeraj Agarwal4 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USAORCID Iconhttps://orcid.org/0000-0003-1076-0428View further author information
ORCID Icon,
Celestia S Higano5 Department of Medicine, University of Washington & Fred Hutchinson Cancer Research Center, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0001-5308-8972View further author information
ORCID Icon,
Cora N Sternberg6 Englander Institute for Precision Medicine, Weill Cornell Department of Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-3938-2627View further author information
ORCID Icon,
Kurt Miller7 Charité – Universitätsmedizin Berlin, Urologische Klinik und Hochschulambulanz, Berlin, GermanyView further author information
,
XiaoLong Jiao8 Bayer HealthCare Pharmaceuticals, Whippany, NJ, USAView further author information
,
Helen Guo8 Bayer HealthCare Pharmaceuticals, Whippany, NJ, USAView further author information
,
Per Sandström8 Bayer HealthCare Pharmaceuticals, Whippany, NJ, USAORCID Iconhttps://orcid.org/0000-0002-8078-9528View further author information
ORCID Icon,
Amanda Bruno8 Bayer HealthCare Pharmaceuticals, Whippany, NJ, USAView further author information
,
Frank Verholen9 Bayer Consumer Care AG, Basel, SwitzerlandView further author information
,
Fred Saad10 University of Montreal Hospital Center, Montreal, Quebec, CanadaORCID Iconhttps://orcid.org/0000-0003-2986-5617View further author information
ORCID Icon &
Neal Shore11 Carolina Urologic Research Center, Myrtle Beach, SC, USAORCID Iconhttps://orcid.org/0000-0001-5767-0548View further author information
ORCID Icon show all
Pages 35-45 | Received 16 Jul 2021, Accepted 20 Sep 2021, Published online: 12 Oct 2021

References

  • Shore N , HiganoCS, GeorgeDJet al. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis.23(4), 680–688 (2020).
  • Nuhn P , DeBono JS, FizaziKet al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur. Urol.75(1), 88–99 (2019).
  • Khalaf DJ , AnnalaM, TaavitsainenSet al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, Phase II, crossover trial. Lancet Oncol.20(12), 1730–1739 (2019).
  • Mori K , MiuraN, MostafaeiHet al. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis.23(4), 539–548 (2020).
  • Parker C , CastroE, FizaziKet al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.31(9), 1119–1134 (2020).
  • Eliasson L , DeFreitas HM, DeardenL, CalimlimB, LloydAJ. Patients' preferences for the treatment of metastatic castrate-resistant prostate cancer: a discrete choice experiment. Clin. Ther.39(4), 723–737 (2017).
  • George DJ , SartorO, MillerKet al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin. Genitourin. Cancer18(4), 284–294 (2020).
  • Parker C , NilssonS, HeinrichDet al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med.369(3), 213–223 (2013).
  • XOFIGO (radium-223 dichloride) Summary of Product Characteristics (2021). www.ema.europa.eu/en/documents/product-information/xofigo-epar-product-information_en.pdf
  • XOFIGO (radium Ra 223 dichloride) injection. Prescribing Information (2021). www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf
  • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer 2020 (2021). https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO-ESUR-SIOG-Guidelines-on-Prostate-Cancer-2020v4.pdf
  • De Bono JS , LogothetisCJ, MolinaAet al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med.364(21), 1995–2005 (2011).
  • Scher HI , FizaziK, SaadFet al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med.367(13), 1187–1197 (2012).
  • Ryan CJ , SmithMR, DeBono JSet al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med.368(2), 138–148 (2013).
  • Beer TM , ArmstrongAJ, RathkopfDEet al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med.371(5), 424–433 (2014).
  • Turpin A , PasquierD, MassardC, BerdahJF, CulineS, PenelN. First-line management of metastatic castrate-resistant prostate cancer patients: audit of real-life practices. Bull. Cancer104(6), 552–558 (2017).
  • Kyriakopoulos CE , ChenYH, CarducciMAet al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial. J. Clin. Oncol.36(11), 1080–1087 (2018).
  • Sartor O , ColemanR, NilssonSet al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a Phase III, double-blind, randomised trial. Lancet Oncol.15(7), 738–746 (2014).
  • De Wit R , DeBono J, SternbergCNet al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med.381(26), 2506–2518 (2019).
  • Swarmi U , SinnottJA, HaalandBet al. Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): results from a real-world dataset. J. Clin. Oncol.38(Suppl. 15), Abstract 5537 (2020).
  • Higano C , SaadF, SartorOet al. Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol.38(Suppl. 6), Abstract 32 (2020).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.